Plunkett Research Online: BioXcel Therapeutics

BIOXCEL THERAPEUTICS (BTAI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701......



BioXcel Therapeutics
Ticker: BTAI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 203 643-8060
Fax:
Address: 555 Long Wharf Drive
12th Floor
New Haven, CT 06511 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Contacts Description
Vimal MehtaCEO/Co-Founder/Director/President
Richard SteinhartCFO/Chief Accounting Officer/Senior VP
See More
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701......See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: